Table 2.
Co-expression of HDGF and DDX5 in endometrial cancer.
| Characteristics | N | HDGF and DDX5(%) | P | |||
|---|---|---|---|---|---|---|
| HDGF+/DDX5+ | HDGF+/DDX5- | HDGF–/DDX5+ | HDGF–/DDX5– | |||
| Age | 0.988 | |||||
| < 50 | 42 | 7(16.7) | 3(7.1) | 6(14.3) | 26(61.9) | |
| ≧50 | 80 | 15(18.8) | 6(7.5) | 12(15.0) | 47(58.8) | |
| Menopausal status | 0.647 | |||||
| Premenopausal | 65 | 10(15.4) | 5(7.7) | 8(12.3) | 42(64.6) | |
| Postmenopausal | 57 | 12(21.1) | 4(7.0) | 10(17.5) | 31(54.4) | |
| FIGO stage | 0.003 | |||||
| I+II | 90 | 10(11.1) | 8(8.9) | 10(11.1) | 62(68.9) | |
| III | 32 | 12(37.5) | 1(3.1) | 8(25.0) | 11(34.4) | |
| Histological grading | 0.130 | |||||
| G1 | 44 | 11(25.0) | 4(9.1) | 4(9.1) | 25(56.8) | |
| G2 | 62 | 6(9.7) | 5(8.1) | 10(16.1) | 41(66.1) | |
| G3 | 16 | 5(31.3) | 0(0) | 4(25.0) | 7(43.8) | |
| Depth of myometrial invasion | 0.605 | |||||
| < 50% | 85 | 13(15.3) | 6(7.1) | 14(16.5) | 52(61.2) | |
| ≧50% | 37 | 9(24.3) | 3(8.1) | 4(10.8) | 21(56.8) | |
| Lymph node status | 0.546 | |||||
| Negative | 105 | 17(16.2) | 8(7.6) | 15(14.3) | 65(61.9) | |
| Positive | 17 | 5(29.4) | 1(5.9) | 3(17.6) | 8(47.1) | |